In COPD management, how do inhaled bronchodilators and inhaled corticosteroids differ in their roles?

• A. Inhaled corticosteroids relieve acute dyspnea; bronchodilators reduce inflammation.
• B. Inhaled bronchodilators relieve airflow limitation acutely; ICS reduce airway inflammation and exacerbations.
• C. Bronchodilators cure COPD; ICS have no role.
• D. ICS replace oxygen therapy.

Answer: (B)

The main idea is that these two inhaled therapies serve different purposes in COPD. Bronchodilators open the airway by relaxing the smooth muscle around the bronchi, which quickly improves airflow and relieves breathlessness. They’re about relief of the obstruction and helping patients breathe better right now, with fast-acting options for immediate relief and long-acting ones for ongoing control.

Inhaled corticosteroids, on the other hand, target inflammation inside the airways. By dampening inflammatory cells and mediators, they reduce the frequency of COPD exacerbations and improve overall control over time. They don’t provide rapid symptom relief and take weeks to show benefit, but they help prevent flare-ups.

So, bronchodilators address the present obstruction and symptoms, while ICS address the inflammatory process and decrease exacerbations. They’re often used together, with bronchodilators handling the acute/ongoing airflow limitation and ICS reducing inflammation and future exacerbation risk.